Literature DB >> 14696968

Identification and characterization of the genes encoding human and mouse osteoactivin.

T A Owen1, S L Smock, S Prakash, L Pinder, D Brees, D Krull, T A Castleberry, Y C Clancy, S C Marks, F F Safadi, S N Popoff.   

Abstract

Osteoactivin (OA) is more highly expressed in the bones of osteopetrotic mutant rats (op/op) than in those of their normal littermates and is the homologue of human nmb, a cDNA more highly expressed in melanoma-derived cell lines of low metastatic potential, and of mouse DC-HIL, which has been implicated in endothelial cell adhesion. The human OA gene is found on chromosome 7p15.1 and consists of 11 exons spanning 28.3 kb. Murine OA is encoded by a highly similar gene of 11 exons spanning 20.2 kb on mouse chromosome 6. Human OA uses the same transcriptional initiation site in both bone and kidney as was reported for melanoma cells. OA is expressed in primary human and mouse osteoblast cultures at all stages of differentiation, with increased levels observed concurrently with the expression of osteoblast phenotype markers. OA is also expressed in a wide variety of human and mouse tissues as determined by RT-PCR analysis. Immunohistochemical investigation of OA expression in late mouse embryonic development showed very high, cell-specific expression in the nervous system, basal layer of the skin, germinal cells of hair follicles, and in the forming nephrons of the kidney. Continuing investigation of the cell-specific expression of OA in bone as well as in other tissues will lead to a better understanding of its function in the development of these cell types.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14696968     DOI: 10.1615/critreveukaryotgeneexpr.v13.i24.130

Source DB:  PubMed          Journal:  Crit Rev Eukaryot Gene Expr        ISSN: 1045-4403            Impact factor:   1.807


  19 in total

1.  Induction of matrix metalloproteinase-3 (MMP-3) expression in the microglia by lipopolysaccharide (LPS) via upregulation of glycoprotein nonmetastatic melanoma B (GPNMB) expression.

Authors:  Fangyuan Shi; Shuangyan Duan; Jihong Cui; Xingrong Yan; Hongmin Li; Yingjuan Wang; Fulin Chen; Lihua Zhang; Jun Liu; Xin Xie
Journal:  J Mol Neurosci       Date:  2014-03-30       Impact factor: 3.444

2.  Mutation in Osteoactivin Promotes Receptor Activator of NFκB Ligand (RANKL)-mediated Osteoclast Differentiation and Survival but Inhibits Osteoclast Function.

Authors:  Samir M Abdelmagid; Gregory R Sondag; Fouad M Moussa; Joyce Y Belcher; Bing Yu; Hilary Stinnett; Kimberly Novak; Thomas Mbimba; Matthew Khol; Kurt D Hankenson; Christopher Malcuit; Fayez F Safadi
Journal:  J Biol Chem       Date:  2015-04-02       Impact factor: 5.157

3.  Transgenic Expression of Osteoactivin/gpnmb Enhances Bone Formation In Vivo and Osteoprogenitor Differentiation Ex Vivo.

Authors:  Nagat Frara; Samir M Abdelmagid; Gregory R Sondag; Fouad M Moussa; Vanessa R Yingling; Thomas A Owen; Steven N Popoff; Mary F Barbe; Fayez F Safadi
Journal:  J Cell Physiol       Date:  2016-01       Impact factor: 6.384

4.  Macrophage-derived GPNMB accelerates skin healing.

Authors:  Walison N Silva; Pedro H D M Prazeres; Ana E Paiva; Luiza Lousado; Anaelise O M Turquetti; Rodrigo S N Barreto; Erika Costa de Alvarenga; Maria A Miglino; Ricardo Gonçalves; Akiva Mintz; Alexander Birbrair
Journal:  Exp Dermatol       Date:  2018-04-30       Impact factor: 3.960

Review 5.  The Silver locus product Pmel17/gp100/Silv/ME20: controversial in name and in function.

Authors:  Alexander C Theos; Steven T Truschel; Graça Raposo; Michael S Marks
Journal:  Pigment Cell Res       Date:  2005-10

6.  Comparison of bone morphogenetic protein-2 and osteoactivin for mesenchymal cell differentiation: effects of bolus and continuous administration.

Authors:  Oneida A Arosarena; Fabiola E Del Carpio-Cano; Raul A Dela Cadena; Mario C Rico; Emeka Nwodim; Fayez F Safadi
Journal:  J Cell Physiol       Date:  2011-11       Impact factor: 6.384

7.  Mutation in osteoactivin decreases bone formation in vivo and osteoblast differentiation in vitro.

Authors:  Samir M Abdelmagid; Joyce Y Belcher; Fouad M Moussa; Suzanne L Lababidi; Gregory R Sondag; Kimberly M Novak; Afif S Sanyurah; Nagat A Frara; Roshanak Razmpour; Fabiola E Del Carpio-Cano; Fayez F Safadi
Journal:  Am J Pathol       Date:  2014-01-23       Impact factor: 4.307

8.  Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease.

Authors:  Madeleine V Pahl; Nosratola D Vaziri; Jun Yuan; Sharon G Adler
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 8.237

9.  Glycoprotein non-metastatic melanoma B expression after hepatic ischemia reperfusion and the effect of silibinin.

Authors:  Adamantios Michalinos; Alexandra K Tsaroucha; Maria Lambropoulou; Dimitrios Schizas; Georgia Valsami; Nikolaos Kostomitsopoulos; Michael S Pitiakoudis; Constantinos E Simopoulos
Journal:  Transl Gastroenterol Hepatol       Date:  2020-01-05

10.  Functional Domains and Evolutionary History of the PMEL and GPNMB Family Proteins.

Authors:  Paul W Chrystal; Tim Footz; Elizabeth D Hodges; Justin A Jensen; Michael A Walter; W Ted Allison
Journal:  Molecules       Date:  2021-06-09       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.